Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes.
Despite the large burden of cardiovascular disease on society, abnormal lipid levels, which are associated with an increase in coronary heart disease mortality, are not being adequately managed in many individuals. Poor patient compliance with therapeutic lifestyle changes and lipid-modifying therapies contribute to this treatment gap. If management of lipid levels is to reduce cardiovascular mortality effectively, poor compliance with treatment needs to be understood and addressed. Educating and motivating patients to understand the need for compliance with continued therapy is an important step for ensuring that the benefits of lipid management cited in clinical trials are translated to the general population. This will require a proactive approach from both patients and physicians. Well-tolerated and effective therapies may also help compliance by reducing the incidence of side effects and the need for complex dosing regimens. Suboptimal treatment of lipid levels is currently limiting the effectiveness of primary and secondary prevention of coronary heart disease; methods for improving compliance should be a key strategy to overcoming this problem.